Threshold for optimal administration of plerixafor in autologous peripheral blood stem cell collections through CD34 + cell monitoring based on the experience from two Japanese university hospitals
Threshold for optimal administration of plerixafor in autologous peripheral blood stem cell collections through CD34 + cell monitoring based on the experience from two Japanese university hospitals
复制标题
根据两所日本大学医院的经验，通过 CD34 细胞监测确定自体外周血干细胞采集中普乐沙福最佳给药阈值
DOI：
10.1111/1744-9987.13614
复制
发表时间：
2021
影响因子：
1.9
通讯作者：
Ohsaka Akimichi
中科院分区：
文献类型：
--
作者：
Okubo Mitsuo;Furuta Yoshiaki;Nakamura Yuki;Osawa Toshiya;Tada Naoki;Sawada Tomohiro;Yamatoya Kenji;Sekiguchi Yasunobu;Araki Yoshihiko;Miyake Kazunori;Noguchi Masaaki;Komatsu Norio;Ohsaka Akimichi
Plerixafor于2017年作为干细胞动员增强剂引入日本，但其使用门槛尚不清楚。在这项研究中，我们评估了57例接受Plerixafor治疗的患者(33例多发性骨髓瘤(MM)、24例恶性淋巴瘤(ML)和152例未使用Plerxafor的患者)。当MM患者CD34+细胞预计数在5.50~20个/μL或ML患者CD34+细胞数分别为6和21个/μ/ L时，CD34+细胞数显著增加，其中以普利沙福一次采集率最高(MM组一次采集率为93.3%，ML组为91.7%，P=0.012)。在CD34+细胞预计数<5.5Cells/μL的情况下，用PLERIXAFOR使L在基线基础上至少升高7个细胞/μ是二次采白细胞成功采集的必要条件。监测CD34+细胞数可提高采集效率，降低采集成本。
Plerixafor was introduced to Japan in 2017 as a stem cell mobilization enhancement reagent, but the threshold for its use remains unclear. In this study, we assessed 57 patients treated with plerixafor (33 patients with multiple myeloma (MM) and 24 with malignant lymphoma (ML) and 152 patients without plerixafor administration. When CD34+ cell pre‐counts were between 5.5 and 20 cells/μL in MM or 6 and 21 cells/μL in ML, the CD34+ cell count increased significantly, attaining the highest yield in response to plerixafor (achievement rate by one leukapheresis is 93.3% and 91.7% in MM and ML, atP< .001 andP= .012, respectively). In case the CD34+ cell pre‐count was less than 5.5 cells/μL, an increase of at least 7 cells/μL from baseline by plerixafor was the necessary condition to achieve successful collection through a two‐time leukapheresis. Monitoring CD34+ cell numbers might improve the collection efficiency and reduce the cost.